Describe the company – the elevator pitch…
Neuromod Devices @ is a medical devices company which has developed an innovative tinnitus treatment called mutebutton®. The first multisensory treatment for tinnitus, the mutebutton® technology is based on neuromodulation, a growth branch of medicine that uses sensory stimulation to promote neuroplasticity (the brains ability to learn and re-learn).
How are you different?
The mutebutton® device is a revolutionary, non-surgical medical device designed to deliver a self-administered treatment for subjective tinnitus. The device is designed for the treatment of subjective tinnitus which is most commonly associated with high frequency hearing loss.
This treatment combines synchronous audio and lingual (tongue) stimulation to promote neuroplasticity in order to reduce tinnitus loudness. The mutebutton system plays relaxing audio through the headphones in synchronisation with the tactile stimulation of the tongue through the tonguetip. The aptly named ‘tonguetip’ rests on the tip of the patient’s tongue, delivering stimulation to the lingual nerves. This synchronous stimulation promotes neuroplasticity in order to reduce the loudness of tinnitus. The mutebutton system has been shown to gradually reduce the loudness of tinnitus.
Independent clinical studies have shown a mean minimum masking level reduction amongst patients of 8.6dB following 10 weeks (70 days) of recommended use. This equates to a 42% reduction in tinnitus loudness within the period. Studies were performed by National University of Ireland Maynooth in associations with The Hermitage Clinic, Dublin.
— Neuromod Devices (@NeuromodDevices) April 24, 2015
Why will the company / product do well?
The product offers a new standard of care for tinnitus, which affects 1 in 10 people. Building on 10 years of research, the device is clinically proven to gradually reduce tinnitus loudness and has been awarded a medical device CE Mark. The device was launched in Ireland December 2014, ahead of a wider European launch in 2016.
Where are you based? (& How is the broadband?), How long will you stay there?
We are headquartered in NexusUCD, a hub that aids the evolution of UCD’s innovation ecosystem. Having recently relocated to NexusUCD, we hope to be staying here for the foreseeable future.
When was the company launched?
The company was founded in late 2010 by Dr. Ross O’Neill who was involved in the original research at NUI Maynooth. Our first product mutebutton® was first launched in Ireland in December 2014.
What have been your biggest wins to date?
Key milestones for us include-
- Securing ISO13485 accreditation as a company, which certifies our ability to meet the highest international quality standards in the design & manufacture medical devices
- Securing the Medical Device CE Mark for mutebutton®, which grants approval to sell the device across all European markets and international markets that recognise the European CE mark
- Launching mutebutton® in Ireland and opening The Neuromod Clinic in Dublin
- Winning Emerging Tech Company of 2014/2015 at the Irish Medical Technology Excellence Awards
- Securing distribution agreements for mutebutton® for foreign markets
— Neuromod Devices (@NeuromodDevices) February 18, 2015
What type of people are you trying to attract to your product?
We are specifically targeting people who suffer from persistent subjective tinnitus. Historically, tinnitus suffers have tended to be men and women over the age of 50. In more recent times, tinnitus is also becoming more prevalent in younger individuals, it is thought that this shift is caused by the increased exposure to loud noise, such as music.
Tell us about your team?
The company has 15 staff, with varied expertise in R&D, Marketing, Sales, Medicine and Quality Management. Dr Ross O’Neill is the founder and CEO of Neuromod Devices. A medtech entrepreneur and biomedical engineer O’Neill is passionate about neuromodulation and committed to the research, development, clinical evaluation and commercialisation of non-surgical neuromodulation technologies for the treatment of unaddressed neurological disorders.
What are you long term plans for your product / company?
We are focussed on preparing for our 2016 European Launch and hope to secure FDA approval in the coming months, to enable a US Launch in 2017. We aim to increase awareness of tinnitus, establish mutebutton® as the new standard of care for the condition and develop new compelling treatments for other chronic neuropathologies.
How can people contact you?
You can check out our website , email us at [email protected] or speak to us directly by calling 1890 221 221 (outside of Ireland +353 1 253 1441). You can also connect with us via social media through Facebook , Twitter and Linkedin.
If you would like to have your company featured in the Thursday edition of the Irish Tech News Business Showcase, get in contact with me on [email protected]